| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Allergy and Immunology, Pulmonary/Respiratory, Hepatology, Gastroenterology, Family Medicine, Internal Medicine |
| Credits Available: | 4.75 AMA PRA Category 1 Credit™, ABIM MOC |
Given the alarmingly high rate of underdiagnosis and the wide clinical variability of liver manifestations, it is critical to advance the management of patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATD-LD). This essential online CME course directly addresses the persistent challenge of diagnostic delay, which is often rooted in the perception that AATD is primarily a lung condition, leading to the frequent oversight of liver disease progression, especially when pulmonary symptoms are not prominent.
Gain crucial, practical expertise in the complete diagnostic pathway for AATD-LD by mastering the appropriate use and interpretation of serum AAT testing, phenotyping, genotyping, and state-of-the-art non-invasive liver assessment tools, thereby deepening your understanding of the disease's natural history and genotype-specific liver risks to improve long-term patient outcomes.
Before launching into the activity content, reflect on what you already know about the diagnosis, management, and emerging research on AATD-LD.
Review the disease burden of AATD-LD, the impact of a late diagnosis on care, clinical presentation and diagnostic pathways, and the screening and referral process for AATD-LD.
This module will review the genotype- and phenotype-specific spectrum of AATD-LD and monitoring strategies for long-term consequences including fibrosis, cirrhosis, and hepatocellular carcinoma. It will identify proper risk-mitigation strategies and review the patient impact.
Review the current standard of care management options for AATD-LD and their limitations. Learn about new and emerging therapies that show promise in clinical trials.
Review what you have learned about AATD-LD. This short assessment reviews the program’s content and provides you with new information to support your clinical practice.
Join this live discussion for a healthy discourse on the pathophysiology, recognition, and diagnostic pathway of AATD-LD. Deepen your understanding of screening guidelines and underdiagnosis. We’ll also discuss transitioning care for pediatric patients, patient burden, and quality of life concerns.
A middle-aged man with non-specific symptoms with elevated liver enzymes on routine blood work
A middle-aged woman with a history of Pi*ZZ variant of AATD-LD now with increasing liver enzymes and COPD exacerbations
Please share one actionable step you will implement to improve outcomes for your patients with AATD-LD.
Join this discussion for a lively chat on monitoring frequency for complications of AATD-LD. We'll chat about resource utilization and how to manage pushback. Discuss with your colleagues about how you integrate clinical trials into patient care for AATD-LD and which new treatments most excite you.
